Background-Children undergoing congenital heart surgery often receive corticosteroids with the aim of reducing the inflammatory response after cardiopulmonary bypass; however, the value of this approach is unclear. Corticosteroids were associated with longer length of stay (least square mean difference, 2.18 days; 95% confidence interval, 1.62 to 2.74 days), greater infection (odds ratio, 1.27; 95% confidence interval, 1.10 to 1.46), and greater use of insulin (odds ratio, 2.45; 95% confidence interval, 2.24 to 2.67). There was no difference in duration of ventilation. In analysis stratified by RACHS-1 category, no significant benefit was seen in any group, and the association of corticosteroids with increased morbidity was most prominent in RACHS-1 categories 1 through 3. Conclusion-In this observational analysis of children undergoing congenital heart surgery, we were unable to demonstrate a significant benefit associated with corticosteroids and found that corticosteroids may be associated with increased morbidity, particularly in lower-risk patients. (Circulation. 2010;122:2123-2130.)
M any children undergoing congenital heart surgery receive perioperative corticosteroids with the aim of reducing postoperative inflammation and capillary leak after cardiopulmonary bypass. 1 Numerous studies have shown a reduction in various inflammatory markers associated with the administration of corticosteroids before or during cardiopulmonary bypass. 2, 3 However, the impact of corticosteroids on clinical outcomes is less clear, with some studies suggesting improvement in outcomes such as postoperative length of stay and duration of ventilation and others not showing a significant difference. [2] [3] [4] [5] In addition, there are limited data on the impact of corticosteroids on perioperative mortality and the potential risks of corticosteroids in this setting, which include hyperglycemia and infection. A recent meta-analysis did not show a significant reduction in duration of ventilation or intensive care unit (ICU) length of stay associated with corticosteroids in children undergoing congenital heart surgery. 6 There were too few deaths to assess mortality because data from only 127 children in 4 trials could be pooled for this analysis, and safety was not assessed. Thus, the impact of corticosteroids in children undergoing congenital heart surgery remains unclear, and survey data suggest wide variation from center to center in the use of corticosteroids in this population. 1 
Clinical Perspective on p 2130
The purpose of this study was to evaluate the efficacy and safety associated with corticosteroids in a large multiinstitutional cohort of children undergoing congenital heart surgery. Specifically, we examined the impact of corticosteroids on postoperative mortality, length of stay, and duration of ventilation, as well as potential morbidities such as hyperglycemia and infection.
Methods

Data Source
Data for this multicenter retrospective cohort study were obtained from the Pediatric Health Information System Database, which contains resource use data from 39 freestanding, tertiary care children's hospitals affiliated with the Child Health Corporation of America (Shawnee Mission, Kan). Pediatric Health Information System-participating hospitals, which account for 20% of all tertiary care children's hospitals, provide discharge data, including patient demographics, diagnoses, and procedures. Billing data are also available detailing medications, imaging studies, laboratory tests, and supplies charged to each patient. Data quality and reliability are ensured through a joint effort between the Child Health Corporation of America and participating hospitals. Systematic monitoring ensures data quality, including bimonthly coding consensus meetings, coding consistency reviews, and quarterly data quality reports. The Children's Hospital of Philadelphia Committees for the Protection of Human Subjects approved this study with a waiver of informed consent.
Study Population
Centers with an average annual congenital heart surgery volume of Ն50 cases per year were eligible for inclusion. Children Յ18 years of age discharged from these centers between January 1, 2003, and December 31, 2008, who underwent congenital heart surgery classified in any of the Risk Adjustment for Congenital Heart Surgery, Version 1 (RACHS-1) categories were included. 7 The RACHS-1 method has been used extensively in risk stratification of patients undergoing congenital heart surgery. 8, 9 It consists of 6 categories of mortality risk, with category 1 being lowest risk and category 6 being the highest risk. 7 Cases in which cardiopulmonary bypass was not used for surgery were excluded.
Data Collection and Study Definitions
Corticosteroid recipients were defined as those who received any type of corticosteroid (methylprednisolone, prednisolone, dexamethasone, or hydrocortisone) on the day before or day of surgery. Medication data in the Pediatric Health Information System Database are derived from the hospital bill and reflect those medications charged to the patient. Corticosteroids administered intravenously or directly into the cardiopulmonary bypass circuit were included in the analysis. A query was performed at an institution that is known to administer corticosteroids directly in the cardiopulmonary bypass circuit to confirm that this mode of administration was captured in the database. Other variables collected included patient age, sex, race/ethnicity, weight (for neonates), prematurity (International Classification of Diseases, ninth revision, codes 765.0x through 765.3x), any genetic syndrome/chromosomal abnormality (International Classification of Diseases, ninth revision, diagnosis codes 758.0 through 758.9, 553.3, 756.6 through 756.7, and 759.7 through 759.9), and primary payor (private insurance, government insurance, other). Center characteristics collected included region and average annual congenital heart surgery volume (for surgeries included in the RACHS-1 categories) during the study period.
Outcome Measures
The primary outcome was in-hospital mortality. Secondary outcomes included total and ICU lengths of stay, duration of postoperative mechanical ventilation, postoperative infection, and postoperative insulin use (which was used as a surrogate for hyperglycemia). Postoperative infection was defined as a diagnosis code for mediastinitis (519.2), wound infection (998.3 or 998.5), or sepsis (038.xx, 995.91, or 995.92) and Ն7 consecutive days of intravenous antibiotics administered in the postoperative period within 30 days of surgery. This timeframe was chosen because it is the standard used in the definition of postoperative infection and is generally accepted as the period of impaired immune response after systemic corticosteroid administration. 10 Postoperative insulin use was defined as the administration of intravenous insulin in the postoperative period within 30 days of surgery, excluding those with a diagnosis code for diabetes (250.xx).
Statistical Analysis
Study variables were summarized using frequencies and percentages for categorical variables and median and interquartile range or means and SDs for continuous variables. Patient and center characteristics were compared between corticosteroid recipients and nonrecipients with the 2 and Wilcoxon rank-sum tests. The distribution of corticosteroid use by center was evaluated and compared with center average annual volume of RACHS-1-classified surgeries using the Spearman correlation. Outcomes in corticosteroid recipients and nonrecipients were compared in unadjusted analyses in the overall cohort and stratified by RACHS-1 category using 2 and Wilcoxon rank-sum tests. Similar to previous studies using the RACHS-1 classification, we combined RACHS-1 categories 5 and 6 for analysis because of the small number of patients in RACHS-1 category 5. 8 Stratified analysis was performed to evaluate whether the impact of corticosteroids on outcome varied by RACHS-1 risk category.
Propensity scores were then constructed using multivariable logistic regression to estimate the likelihood of receiving corticosteroids given an observed set of baseline confounders. [11] [12] [13] Variables entered into the model included age, sex, race/ethnicity, prematurity, genetic syndrome, RACHS-1 category, center, and mean annual center volume. Patient weight (for neonates) was initially considered but was not included in the final model because it was highly collinear with prematurity. All 2-term interactions were tested and none were significant. The propensity model c statistic was 0.86. Propensity score distributions overlapped between the corticosteroid and no corticosteroid groups ( Figure I in the online-only Data Supplement).
Multivariable analysis was performed to evaluate outcomes independently associated with corticosteroids, adjusting for propensity score and each individual covariate described above. 14, 15 Models with and without propensity score in addition to the individual covariates were compared using the Akaike information criterion, with a smaller AIC representing a better model. 16 The Akaike information criterion was smaller for models of all outcome measures incorporating the propensity score in addition to the individual covariates (except for 1 outcome for which Akaike information criterion was similar), indicating better model performance with the propensity score included. Thus, both propensity score and individual covariates were included in all models. For dichotomous outcome variables, modeling consisted of logistic regression using the method of generalized estimating equations. For continuous outcome variables, mixed-effect models were used, treating center as a random effect. This analytic strategy accounts for unexplained between-hospital variation by treating observations within a hospital as clustered (correlated). Odds ratios and 95% confidence intervals are reported for the generalized estimating equation models, as well as difference in least square means and 95% confidence intervals comparing corticosteroid recipients and nonrecipients from the mixed-effects models. Analyses were performed for the overall cohort and stratified by RACHS-1 category. A subanalysis was also performed in neonates (Յ28 days old at surgery) because previous studies have suggested that this subgroup may receive the most benefit from corticosteroids. 4, 17, 18 Finally, a sensitivity analysis was performed to compare results using 2 different propensity score methodologies: the methodology outlined above (which incorporated nontransformed propensity scores into the models for all outcome measures, along with individual covariates) or the methodology using inverse probabilityweighted estimators incorporating propensity score entered into the models, along with individual covariates.
All analyses were performed with SAS version 9.2 (SAS Institute, Cary, NC). The conservative Bonferroni correction was used to account for multiple comparisons. 19 Thus, a value of PϽ0.008 was considered statistically significant.
Results
Patient Characteristics and Corticosteroid Use
A total of 46 730 patients from 38 centers were included (Table  1) . Overall, 55% were male, and the median age was 8 months (interquartile range, 2 months to 4 years). The study population comprised patients from diverse ethnic/racial backgrounds, included those with government and private insurance, and represented a wide range of hospital size and geographic location.
Fifty-four percent of patients (nϭ25 113) received perioperative corticosteroids. The use of corticosteroids was associated with younger age, white race, prematurity, genetic abnormality, higher RACHS-1 category, government insurance, and being treated at a center in the south or north central United States (Table 1) . Corticosteroid use by center varied, with a range of 1% to 96% of patients per center receiving corticosteroids (the Figure) . There was no significant linear correlation seen between center volume and use of corticosteroids (Pϭ0.62). Methylprednisolone was the most common perioperative corticosteroid used (69.8%), followed by dexamethasone (26.6%) and hydrocortisone (3.6%). Corticosteroids were most often given on the day of surgery only (79.1%), followed by the day before and day of surgery (12.2%), and the day before surgery only (8.9%). Of note, 35.4% of patients in the perioperative corticosteroid recipient group and 27.8% of patients in the nonrecipient group received at least 1 dose of a corticosteroid at some point in the postoperative period.
Outcomes
Unadjusted outcomes are displayed in Table 2 (overall) and Table I in the online-only Data Supplement (stratified by RACHS-1 category). Adjusted outcomes for the overall cohort are displayed in Table 3 . In multivariable analysis, there was no difference in mortality. Corticosteroid recipients had longer total and ICU lengths of stay and greater postoperative infection and use of insulin. Of note, in the group that received postoperative insulin, insulin was initiated at median postoperative day 0 (interquartile range, 0 to 3 days) after surgery. There was no difference in postoperative duration of mechanical ventilation. In multivariable analysis stratified by RACHS-1 category, no significant benefit was seen in any group, and the association of corticosteroids with increased morbidities was most prominent in RACHS-1 categories 1 through 3 ( Table 4 ). The absolute number of deaths in RACHS-1 category 1 was small (steroid recipients [nϭ26] 1.3% versus nonrecipients [nϭ6], 0.3%).
In a subanalysis of 10 018 neonates, corticosteroids were associated with significantly longer postoperative ICU length of stay and greater use of postoperative insulin. There were no other significant differences in outcomes (Table 5) .
In sensitivity analysis performed to compare the results from propensity score methodology reported above (use of nontransformed propensity score and individual covariates in the models) and the methodology using inverse probabilityweighted estimators incorporating propensity score entered into the models, along with individual covariates, results were unchanged (data not shown).
Discussion
In this large multicenter observational analysis, we were unable to demonstrate a significant benefit associated with the use of corticosteroids and found that corticosteroids may be associated with increased morbidity, particularly in lowerrisk patients. Cardiopulmonary bypass triggers the release of various proinflammatory and vasoactive agents, leading to a postoperative systemic inflammatory response and capillary leak syndrome. 20 -22 This can lead to multisystem dysfunction, contributing to substantial postoperative morbidity and mortality. 6,20 -22 Thus, the aim of corticosteroid administration is to attenuate this inflammatory response and associated adverse outcomes.
Results from our study confirm that corticosteroids are used commonly, with more than half (nϭ25 113) of children undergoing congenital heart surgery at 38 US hospitals receiving corticosteroids over the 5-year period from 2003 to 2008. 1 However, we also found wide variation in measured practice patterns, with some centers using corticosteroids in nearly all patients and some using corticosteroids very infrequently. This variation in practice may reflect the uncertainty about the benefits of corticosteroids in this setting and the conflicting results demonstrated by previous studies. Although numerous adult and pediatric studies have demonstrated that corticosteroids are effective in reducing postoperative levels of inflammatory markers such as interleukins, tumor necrosis factor, and C-reactive protein, the impact of corticosteroids on clinical outcomes is less clear. 2, 3, 23 In adults, a meta-analysis combining results from 44 randomized trials of corticosteroid use in patients undergoing cardiac surgery and cardiopulmonary bypass found that corticosteroids were associated with a significant reduction in postoperative atrial fibrillation and a small but statistically significant reduction in length of stay. 24 There was no significant impact on mortality. Other safety outcomes were not assessed. There are currently 2 ongoing large clinical trials in the adult population examining the efficacy and safety of methylprednisolone and dexamethasone in patients undergoing cardiac surgery. 25, 26 A meta-analysis has also been performed in the pediatric population. 6 This analysis did not show any significant difference in outcomes, including duration of ventilation or ICU length of stay, associated with corticosteroids in children undergoing congenital heart surgery. 6 Data from only 127 children in 4 trials could be pooled for this analysis because of poor study design, varying inclusion and exclusion criteria between studies, and heterogeneity in outcomes reported. There were too few deaths in these small trials to assess the impact of corticosteroids on mortality. Our multicenter study evaluating Ͼ40 000 children supports the results from these small trials in that we did not find a benefit relative to length of stay or duration of mechanical ventilation associated with 
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corticosteroid administration in this setting. Our large sample size also allowed assessment of mortality, and a benefit was not seen. A possible reason that the attenuation of inflammation associated with corticosteroid administration in this setting is not translated to a clinical benefit is that corticosteroids alone may not address the complex, multifaceted nature of the inflammatory response after cardiopulmonary bypass. Several studies have shown that although corticosteroids can reduce levels of certain inflammatory markers, this effect is not universal. Lindberg et al 2 found that administration of dexamethasone to children undergoing congenital heart surgery did not decrease von Willebrand factor antigen (a marker of endothelial activation) or S100B (a marker of blood/brain barrier dysfunction). Jansen et al 27 found that complement activation was not diminished with multiple different regimens of corticosteroids. Alternatively, it is possible that only certain regimens of corticosteroids are effective in this setting. For example, it has been suggested that a regimen combining preoperative and intraoperative administration of corticosteroids may be more effective at attenuating the inflammatory response than the use of only intraoperative administration in both animal and human models. 4, 28 In this study, we were not able to assess the dose of corticosteroids given or exact timing in relation to surgery.
In our stratified analysis by RACHS-1 category, no significant benefit was seen in any group, and the association of corticosteroids with increased morbidity was most prominent in the lower-risk groups (RACHS-1 categories 1 through 3). We also found an increased mortality risk associated with corticosteroids in RACHS-1 category 1. Although statistically significant, the absolute number of deaths in this category was small. It is possible that in the lower-risk categories the balance between potential risks and benefits of corticosteroid therapy is shifted toward favoring relatively greater risk. The lower-risk surgeries are generally associated with shorter cardiopulmonary bypass times and attenuated postoperative inflammatory response compared with surgeries with longer cardiopulmonary bypass times. 29 Thus, not much benefit from the antiinflammatory properties of corticosteroids would be expected, and the potential risks of corticosteroid therapy may have a relatively greater impact on outcome.
In the evaluation of specific morbidities, we found that corticosteroid administration was associated with more frequent infection, more frequent use of postoperative insulin, and prolonged length of stay. Although we cannot know for certain that the use of postoperative insulin was related to hyperglycemia, this is likely the most common reason for its use in the postoperative period. It is also likely that center practices relative to insulin administration for hyperglycemia differ; however, we attempted to account for this and other center-related differences in our analytic strategy by adjusting for center-level factors and accounting for between-hospital variation through treating observations within a hospital as clustered (correlated) observations. Previous analyses have demonstrated that hyperglycemia can predispose to poor outcomes, including infection, prolonged length of stay, and increased mortality in critically ill children. 30 -32 The rate of postoperative infection identified in our analysis (2.9%) is similar to that reported in clinical registry data (2.8%) in the congenital heart surgery population. 33 Our results relative to infection differ from a recent meta-analysis in the adult population that showed that the administration of perioperative corticosteroids did not increase the risk of infection. 34 Previous analyses in the pediatric population have shown that postoperative infection in children undergoing congenital heart surgery has been associated with prolonged length of stay and increased mortality. 33, 35 Perioperative morbidities such as prolonged length of stay may also have an important impact on longer-term outcomes in that prior studies have shown prolonged hospital stay to be an independent predictor of future neurodevelopmental status in patients undergoing congenital heart surgery. 36 
Limitations
This study is subject to the limitations of any observational investigation, including selection bias and the potential impact of confounders. Although we attempted to account for this in our analytic strategy through the use of propensity scores and adjustment for known patient and center confounders, there may be other unmeasured patient or center factors that affect the receipt of corticosteroids and/or outcome. These may include, among other factors, those relating to cardiopulmonary bypass protocols, which may vary from center to center, such as the use of modified ultrafiltration. 37, 38 Because the purpose of our study was to assess the relationship between preoperative corticosteroid administration and outcome, we did not adjust for postoperative factors or complications, including the administration of postoperative corticosteroids, because it is possible that these factors may be in the causal pathway between our predictor variable of interest and outcome. Conversely, it is possible that some of these factors may also be confounding factors not accounted for in the analysis.
Our study is also subject to the limitations of the database. We were unable to evaluate the impact of different dosing regimens or the exact timing of corticosteroid administration in relation to surgery because this information is not collected in the database. Relative to our evaluation of potential morbidities, we were unable to assess laboratory values such as glucose levels. Instead, we evaluated the use of postoperative insulin. However, it is likely that there are patients with hyperglycemia who do not receive insulin and that practices relative to insulin administration differ across centers. Our analytic strategy attempts to account for this and other factors that may vary by center by adjusting for center-level variables and treating observations within a hospital as correlated observations. However, this strategy may not account for all potential differences between centers. In addition, there may be other unmeasured factors affecting glucose levels and thus use of insulin in the postoperative period. Among these factors are duration of cardiopulmonary bypass and the use of deep hypothermic circulatory arrest. 39, 40 Finally, the accuracy of coding of congenital heart surgery in administrative data sets is not known. Random coding errors may be mitigated by the use of large data sets and groupings of procedures, as in this study. The similarities between overall outcomes of patients undergoing congenital heart surgery in our data set compared with other large clinical data sets support the validity of our data. 33, 41 
Conclusions
In this multicenter observational analysis of children undergoing congenital heart surgery, we were unable to demonstrate a significant benefit associated with corticosteroids, and we found that corticosteroids may be associated with increased morbidity, particularly in lower-risk patients. These data indicate the need for an adequately powered clinical trial in high-risk patients to evaluate the efficacy and safety of corticosteroids in this population. Further analysis focusing on the potential impact of different dosing regimens and timing of corticosteroid administration relative to surgery may help to inform the design of a future trial. 
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